AMENDMENTS TO THE CLAIMS

Claims Listing

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method of detecting cancer-associated anti-tumor autoantibodies in a sample from an individual, comprising:

contacting the sample with an immunoassay reagent; and

detecting a presence of complexes formed by specific binding of the immunoassay reagent to any cancer-associated anti-tumor autoantibodies present in the sample,

wherein the immunoassay reagent comprises one or more tumor marker proteins prepared from a bodily fluid~~, derived~~ from a body cavity or space in which a tumor is or was present or associated with in one or more cancer patients

wherein said one or more tumor marker proteins exhibit selective reactivity with cancer-associated anti-tumor autoantibodies, and wherein detection of complexes indicates the presence of cancer-associated anti-tumor autoantibodies in the individual.

2. (Previously presented) The method of Claim 1, further comprising detecting and/or quantitatively measuring the presence of two or more types of autoantibodies, wherein each one of the two or more types of the autoantibodies is immunologically specific to a different tumor marker protein or to different epitopes of the same tumor marker protein, wherein the immunoassay is carried out using a panel of two or more immunoassay reagents, at least one of which comprises the tumor marker protein of Claim 1.

3. (Previously presented) The method of Claim 1, wherein the sample is a bodily fluid obtained from a patient in need of detection or diagnosis of cancer, and wherein detection of the presence of an elevated level of the anti-tumor autoantibodies in the sample,

as compared to a sample from a normal control, indicates that the patient in need of detection or diagnosis of cancer has or is developing a cancer.

4. (Previously presented) The method of Claim 1, wherein the sample is a sample of a bodily fluid obtained from a patient in need of monitoring of progress of cancer or other neoplastic disease, and wherein detection of the presence of an elevated level of the anti-tumor autoantibodies in the sample, as compared to a sample from a normal control, indicates the progress of cancer or other neoplastic disease in the patient in need of monitoring of progress of cancer or other neoplastic disease.

5. (Previously presented) The method of Claim 1, wherein the sample is a bodily fluid obtained from an asymptomatic subject, and wherein detection of the presence of an elevated level of the anti-tumor autoantibodies in the sample, as compared to a sample from a normal control, indicates early neoplastic or early carcinogenic change in the asymptomatic subject.

6. (Previously presented) The method of Claim 1, wherein the sample is a bodily fluid obtained from an asymptomatic human subject selected from a population of asymptomatic human subjects in need of a screening for a risk of developing cancer, and wherein detection of the presence of an elevated level of the anti-tumor autoantibodies in the sample, as compared to a normal control, identifies the asymptomatic subject as being at risk of developing cancer.

7. (Previously presented) The method of Claim 1, wherein the sample is a bodily fluid obtained from a cancer patient in need of monitoring a response of the cancer patient to an anti-cancer treatment, and wherein the presence of a decreased level of the anti-tumor autoantibodies in a sample after the anti-cancer treatment as compared to the level of the anti-tumor autoantibodies in a sample before the anti-cancer treatment indicates that the patient has responded positively to the treatment.

8. (Previously presented) The method of Claim 1, wherein the sample is a bodily fluid obtained from a patient in need of detection of a recurrent disease, wherein the patient was previously diagnosed as having cancer and has undergone anti-cancer treatment to reduce amount of cancer, and wherein presence of an increased level of autoantibodies in the patient, as compared to a normal control, indicates that the cancer has recurred.

Claims 9-10. (Cancelled)

11. (Previously presented) The method of Claim 1, wherein the bodily fluid is ascites fluid, pleural effusion, seroma, hydrocoele or wound drainage fluid.

12. (Previously presented) The method of Claim 3, wherein the bodily fluid is ascites fluid, pleural effusion, seroma, hydrocoele or wound drainage fluid.

Claims 13-14. (Cancelled)

15. (Withdrawn) The method according to claim 11, wherein the tumor marker protein is selected from MUC1, MUC16 or c-myc.

16. (Withdrawn) The method according to claim 12, wherein the tumor marker protein is selected from MUC1, MUC16 or c-myc.

17. (Withdrawn) The method according to any one of claims 1, 2, or 10, wherein the tumor marker protein is selected from c-erbB2, p53, ras, BRCA1, BRCA2, APC, PSA, CEA, and CA19.9.

18. (Withdrawn) The method according to claim 3, wherein the tumor marker protein is selected from c-erbB2, p53, ras, BRCA1, BRCA2, APC, PSA, CEA and CA19.9.

Claims 19-38. (Cancelled)